Skip to main content

Khattar Jack A.'s Form 4 filing

Supernus Pharmaceuticals, Inc. (SUPN) · filed Oct 10, 2025

Accession no.
0001628280-25-044830
Filed
Oct 10, 2025
Trade date
Oct 9, 2025
Filing delay
1 day
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $3.03M. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Khattar Jack A.CIK 0001539937Director, Officer (President, CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 9, 2025Common StockMOption exerciseAcquired+81,250$25.30+$2,055,6251,266,478Direct
Oct 9, 2025Common StockSSaleDisposed−58,371$50.55−$2,950,654.051,208,107Direct
Oct 9, 2025Common StockSSaleDisposed−1,529$51.46−$78,682.341,206,578Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Oct 9, 2025Common StockMOption exerciseDisposed−81,250$0.00$00Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)